| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.25▼ | 1.27▼ | 1.27▼ | 1.27▼ | 1.53▼ |
| MA10 | 1.26▼ | 1.27▼ | 1.24▼ | 1.45▼ | 1.74▼ |
| MA20 | 1.27▼ | 1.24▼ | 1.26▼ | 1.69▼ | 2.11▼ |
| MA50 | 1.27▼ | 1.28▼ | 1.36▼ | 1.93▼ | 1.56▼ |
| MA100 | 1.25▼ | 1.39▼ | 1.60▼ | 2.27▼ | 1.29▼ |
| MA200 | 1.28▼ | 1.64▼ | 1.79▼ | 1.84▼ | 16.96▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.004▼ | 0.005▲ | 0.011▲ | -0.053▼ | -0.181▼ |
| RSI | 30.422▼ | 45.401▼ | 42.165▼ | 26.937▼ | 43.132▼ |
| STOCH | 16.667▼ | 62.886 | 71.922 | 6.598▼ | 7.159▼ |
| WILL %R | -100.000▼ | -44.000 | -58.824 | -89.634▼ | -96.473▼ |
| CCI | -179.487▼ | -30.769 | 0.000 | -97.627 | -142.721▼ |
|
Thursday, April 02, 2026 04:47 PM
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company product is REQORSA immunogen therapy drug for ...
|
|
Tuesday, March 10, 2026 04:00 AM
AUSTIN, Texas, March 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...
|
|
Saturday, March 07, 2026 05:54 PM
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/04/26 | 1.21 | 1.29 | 1.21 | 1.235 | 459,639 |
| 10/04/26 | 1.30 | 1.34 | 1.15 | 1.15 | 604,924 |
| 09/04/26 | 1.29 | 1.355 | 1.27 | 1.30 | 347,675 |
| 08/04/26 | 1.39 | 1.44 | 1.2602 | 1.31 | 631,505 |
| 07/04/26 | 1.46 | 1.46 | 1.32 | 1.37 | 310,052 |
| 06/04/26 | 1.52 | 1.57 | 1.42 | 1.45 | 444,374 |
| 02/04/26 | 1.50 | 1.57 | 1.43 | 1.54 | 392,276 |
| 01/04/26 | 1.81 | 1.82 | 1.55 | 1.58 | 591,383 |
| 31/03/26 | 1.73 | 1.82 | 1.725 | 1.81 | 144,434 |
| 30/03/26 | 1.84 | 1.8697 | 1.73 | 1.77 | 270,088 |
|
|
||||
|
|
||||
|
|